Portola Pharma Cmn (PTLA) 20.86 $PTLA Portola

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Portola Pharma Cmn (PTLA) 20.86 $PTLA

Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
GlobeNewswire - Tue Aug 30, 3:18AM CDT
--AndexXa Rapidly Reversed Anticoagulant Effect of Factor Xa Inhibitors; Excellent or Good Hemostasis Was Achieved in 79 Percent of Patients Over 12 Hours--
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA(TM)-4 Study of AndexXa(TM) (andexanet alfa) at European Society of Cardiology 2016 Congress
GlobeNewswire - Fri Aug 26, 7:00AM CDT
Portola Pharmaceuticals Inc. (NasdaqTLA) today announced that interim results from its ongoing Phase 3b/4 ANNEXA(TM)-4 trial of AndexXa(TM) (andexanet alfa), a Factor Xa inhibitor antidote, will be featured in an oral Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 Congress, which will take place from August 27-31 in Rome. The data also will be featured in the ESC's Hot Line - Preventive Strategies II press conference on Tuesday, August 30, at 9:00 a.m. CEST.
PTLA: 20.86 (+0.50)

Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), PTLA: 20.86 (+0.50), CLVS: 23.59 (-1.18), GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), REGN: 393.40 (+0.85)

Portola IndexXa's Regulatory Application Validated in the EU
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:48AM CDT
Portola (PTLA) announced that the European Medicines Agency has accepted to review the company's Marketing Authorization Application for IndexXa.
PTLA: 20.86 (+0.50), ANIP: 61.42 (+1.68), ANIK: 47.94 (+0.70)

Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa(TM) (andexanet alfa), a Factor Xa Inhibitor Antidote
GlobeNewswire - Fri Aug 19, 7:30AM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today announced that the MAA for IndexXa(TM) (andexanet alfa; trade name in the United States is AndexXa(TM)), a Factor Xa inhibitor antidote, has been submitted to the EMA, completed the validation period, and has been accepted for review. IndexXa is in development for patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery. Portola is seeking conditional approval of IndexXa in the EU through the centralized procedure. With the acceptance of the application, the EMA's Committee for Medicinal Products for Human Use (CHMP) will now begin the centralized review procedure under a standard 210-day review period.
PTLA: 20.86 (+0.50)

Portola (PTLA) Stock Down on CRL for AndexXa BLA in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:16AM CDT
Portola (PTLA) received a Complete Response Letter for AndexXa (andexanet alfa) in the U.S.
PTLA: 20.86 (+0.50), ANIP: 61.42 (+1.68), GERN: 2.73 (+0.04), ANIK: 47.94 (+0.70)

Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa(TM) (andexanet alfa)
GlobeNewswire - Wed Aug 17, 9:56PM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for AndexXa(TM) (andexanet alfa). An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Currently, there is no FDA-approved antidote for Factor Xa inhibitors.
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 09, 3:07PM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today provided a corporate update and reported its financial results for the quarter ended June 30, 2016.
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9
GlobeNewswire - Tue Aug 02, 3:07PM CDT
Portola Pharmaceuticals, Inc. (NasdaqTLA) announced today that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2016, and provide a general business overview on Tuesday, August 9, 2016, at 4:30 p.m. ET (1:30 p.m. PT).
PTLA: 20.86 (+0.50)

Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Tue Aug 02, 9:02AM CDT
The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. Stock-Callers.com now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:
TRVN: 6.77 (-0.01), PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), NERV: 12.35 (+0.13)

Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.77 (-0.01), PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), NERV: 12.35 (+0.13)

Corridor Company Case Study Examines Portola Pharmaceuticals' Use of Corridor's CLM Product in Managing All Aspects of Portola's Contract Management Process
PRWeb - Wed Jun 22, 2:48AM CDT
Corridor Company, Inc., the leading provider of contract lifecycle management software powered by the SharePoint and Office 365 platforms, has published a case study about the successful deployment of its Contract Management Business Application for SharePoint, CM[.app], by Portola Pharmaceuticals, a biopharmaceutical company with a foundation of products and product candidates that significantly advances patient care in the areas of thrombosis, other hematologic disorders and inflammation. Portola's legal and finance teams now use Corridor's software to manage their entire contract lifecycle, including contract creation and request, negotiation with external parties, documented approval, and metadata reporting.
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies.
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Tue May 31, 3:05PM CDT
Portola Pharmaceuticals (NasdaqTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37 Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif.
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
GlobeNewswire - Fri May 27, 7:45AM CDT
--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016--
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa(TM) (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
GlobeNewswire - Mon May 23, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpellier, France. Additionally, new data from pharmacokinetic and mechanism of action studies of the Company's Factor Xa inhibitor antidote AndexXa (andexanet alfa) will be presented in poster sessions.
PTLA: 20.86 (+0.50)

How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 20.86 (+0.50), ANTH: 2.91 (+0.03), VTAE: 6.84 (-0.07), ITCI: 40.63 (+0.29)

Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu May 05, 3:06PM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016.
PTLA: 20.86 (+0.50)

Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Thu Apr 14, 7:00AM CDT
Portola Pharmaceuticals (NasdaqTLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans.
PTLA: 20.86 (+0.50)

3 Biotech Takeover Targets That Could Get Bought Soon
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 2:39PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Biotech stocks have been especially hard hit over the past six months because of concerns over drug prices, and the sell-off within the industry has resulted in bargains that big pharma might find compelling. Among...
MDVN: 80.93 (+0.37), BMRN: 95.19 (+1.30), PTLA: 20.86 (+0.50), KITE: 58.87 (+1.25), AMGN: 170.13 (+0.07), BMY: 56.76 (-0.63)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading